title: Thrombophilia Screening: Universal, Selected, or Neither?
abstract: The utility of thrombophilia testing in clinical practice is still a matter of debate because studies have not shown a benefit in the reduction of recurrent venous thromboembolism (VTE) risk in patients with thrombosis, despite the clearly higher VTE risk for first thrombosis. Screening for thrombophilia is indicated in selected patients. Particularly in selected young patients, especially women of childbearing age, the knowledge of the genetic thrombophilic defect may help in specific situations to decrease the risk of VTE events. Avoidance of modifiable risk factors and/or prophylactic thromboembolic procedures may be evaluated in selected patients. A comprehensive workup including personal and familial history, clinical examination, and laboratory test results including hereditary thrombophilia remains helpful in assessing the cumulative risk and the management of this group of selected patients.
authors.affiliation: 1 Service of Hematology, Clinica Luganese Moncucco, Lugano and synlab Suisse, Lucerne, Switzerland.|2 Diagnostic Hematology, Department of Hematology, University Hospital Basel, Basel, Switzerland.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Colucci
authors.affiliation: 2 Diagnostic Hematology, Department of Hematology, University Hospital Basel, Basel, Switzerland.
authors.forename: Dimitrios A
authors.initials: DA
authors.lastname: Tsakiris
mesh_terms: D005260:Female; D006801:Humans; D008297:Male; D012307:Risk Factors; D019851:Thrombophilia / Q000175:diagnosis* / Q000453:epidemiology / Q000517:prevention & control; D054556:Venous Thromboembolism / Q000175:diagnosis* / Q000453:epidemiology / Q000517:prevention & control
keywords: genetic thrombophilia; thrombophilia screening; venous thromboembolism